Clinical trials
Gastric or Gastroesophageal Junction Adenocarcinoma clinical trials
Below are recruiting gastric or gastroesophageal junction adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 970 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06239194RecruitingPhase 1/Phase 2
MdX2001 for advanced solid tumors
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
Denver, ColoradoAges 18 years+ - NCT06253871RecruitingPhase 1
Study of IAM1363 for HER2 Cancers
This trial tests a new oral drug called IAM1363 for people with HER2-altered cancers that have stopped responding to previous treatments. The goal is to see if the drug is safe and how well it works against these cancers.
La Jolla, CaliforniaAges 18 years+ - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Adelaide, South AustraliaAges 18 years+ - NCT06346197RecruitingPhase 3
Immunotherapy combo for advanced MSI-H stomach/esophageal cancer
This trial tests a combination of immune checkpoint inhibitors (nivolumab, botensilimab, and balstilimab) plus chemotherapy for people with advanced stomach or esophageal cancer that has a specific genetic instability (MSI-H/dMMR) and expresses PD-L1. It may be an option for those who haven't had prior immunotherapy or chemotherapy for advanced disease.
BrestAges 18 years+ - NCT06495606Recruiting
How stomach acid affects your voice
This study looks at how stomach acid backing up into the throat can change the voice. It may help find typical voice differences in people with acid reflux.
BernAges 18 years+ - NCT06503146RecruitingPhase 2
New imaging tracer for detecting various cancers
This trial tests a new imaging agent, [18F]FAPI-74, which might help detect certain cancers more clearly. The scan looks for a protein called fibroblast activation protein (FAP) that is often found in tumors. If you have one of the listed cancers and are about to start treatment, this study could help doctors see where the cancer is and how it responds to therapy.
Bethesda, MarylandAges 18–120 - NCT06550063Recruiting
HER2 status in esophagogastric cancer and patient outcomes
This study looks back at medical records of people with a certain type of esophageal or stomach cancer to see how HER2 status relates to patient outcomes. It may help guide future treatment decisions.
Dublin, LeinsterAges Any age - NCT06632262RecruitingPhase 2
Testing new drugs for cancers with FGFR gene changes
This trial tests two new drugs, ABSK061 and ABSK043, in people whose cancers have specific changes in the FGFR2 or FGFR3 genes. It may be an option if your cancer has stopped responding to standard treatments or if no standard treatment is available.
Guiyang, GuizhouAges 18 years+ - NCT06687603Recruiting
Detecting Barrett's esophagus in people without heartburn
This study aims to screen for Barrett's esophagus in people who are getting a routine colonoscopy but do not have chronic heartburn. It uses a simple, non-invasive cell collection device (EsoCheck) to see if you might have Barrett's esophagus, which can increase the risk of esophageal cancer.
Aurora, ColoradoAges 50 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT07224750Recruiting
A blood test to find early signs of gastrointestinal cancer
This study is testing a blood-based test to detect unique molecules (called miRNAs) that may signal the presence of several types of gut or digestive system cancers. The goal is to develop a simple screening tool that could catch these cancers earlier.
Duarte, CaliforniaAges 18 years+ - NCT06710756RecruitingPhase 1/Phase 2
Lead-212 therapy for solid tumors
This trial tests a new radioactive drug, Lead-212 PSV359, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to find and attack cancer cells.
Miami, FloridaAges 18–90 - NCT06759064RecruitingPhase 1/Phase 2
Intraperitoneal Immunotherapy and Bone Drug for Stomach Cancer Belly Fluid
This trial tests a combination of two drugs—one that helps your immune system fight cancer (immune checkpoint inhibitor) and one that strengthens bones (zoledronic acid)—given directly into the belly (intraperitoneal) to control fluid buildup caused by stomach cancer. It may help people with moderate to severe malignant ascites who have not had local belly treatments or immunotherapy recently.
Jinan, ShandongAges 18–75 - NCT06766305RecruitingPhase 1/Phase 2
QL1706 combined with SOX before and after stomach cancer surgery
This trial tests a new combination of drugs (QL1706 plus chemotherapy SOX) given before and after surgery for stomach or gastroesophageal junction cancer. It aims to shrink the tumor before surgery and help prevent recurrence afterward.
Hangzhou, ZhejiangAges 18–75 - NCT06782412RecruitingPhase 2/Phase 3
New imaging test for different cancers using FAPI-PET
This trial is testing a new imaging method called FAPI-PET to see if it can help find and understand tumors better than standard scans. It is for people with newly diagnosed stomach/esophageal cancer, pancreatic cancer, or those with unclear symptoms or scan results.
EdegemAges 18 years+ - NCT06870630Recruiting
Comparing two myotomy methods for type 2 achalasia
This trial tests two muscle-cutting procedures for people newly diagnosed with type 2 achalasia (a swallowing disorder). The goal is to see if a more complex myotomy works better than the standard one.
Hyderabad, TelanganaAges 18–75 - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07115043RecruitingPhase 1/Phase 2
Study of AZD6750 for advanced solid tumors
This trial tests a new drug called AZD6750 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT07151040RecruitingPhase 1/Phase 2
Testing TH9619 for advanced solid tumors
This trial tests a new drug called TH9619 for people with advanced cancers of the colon, head and neck, lung, or stomach. It aims to see if the drug is safe and works against tumors that have already been treated with chemotherapy.
VillejuifAges 18 years+ - NCT07277439RecruitingPhase 2
Immunotherapy and chemoradiation before surgery for stomach cancer
This study tests combining an immunotherapy drug (PD-1 inhibitor) and a medication to boost your immune system (thymalfasin) with standard chemotherapy and radiation before surgery for stage III cancer where the stomach meets the esophagus. The goal is to see if this approach can shrink the tumor and improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT07389876Recruiting
Second-line treatment for advanced stomach cancer with nab-paclitaxel
This trial tests a new chemotherapy combination for patients with advanced stomach cancer that has worsened after initial treatment. It aims to find a better second-line option using a drug called nab-paclitaxel.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT01048281Recruiting
Study of stomach and esophagus cancer samples
This study looks at stomach (gastric) and esophagus cancer, using clinical information and tissue samples. It may help researchers better understand these cancers and improve future care.
Stanford, CaliforniaAges 18 years+ - NCT07432633RecruitingPhase 1/Phase 2
Imaging scan to detect cancer-linked protein in several tumor types
This trial tests a new PET scan tracer that targets a protein found on certain cancer cells. It may help doctors better see and understand tumors in people with colorectal, gastric, pancreatic, lobular breast, or ovarian cancer.
Dallas, TexasAges 18–80 - NCT07464470Recruiting
Comparing stomach cancer and brain metastasis genetics
This trial studies stomach and esophageal cancers that spread to the brain. It compares the genetic makeup of the original tumor to the brain metastasis, which may help find better treatments.
MoscowAges 18 years+
Hear when a new Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastric or gastroesophageal junction adenocarcinoma?
- Yes. Clin2 currently lists 970 recruiting gastric or gastroesophageal junction adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastric or gastroesophageal junction adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastric or gastroesophageal junction adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Gastric / Gastroesophageal Junction Adenocarcinoma
- AFP Gastric or Gastroesophageal Junction Adenocarcinoma
- Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal Junction (GEJ) Adenocarcinoma
- Advanced Gastroesophageal Junction Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.